Kasing Ho, MD
Internal Medicine · Englewood, NJNPI 1104864925
Payments from drug & device makers
Across 342 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$939
- AbbVie$547
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$491
- Lilly USA, LLC$395
- Johnson & Johnson$386
- AstraZeneca$337
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,572100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $939 |
| AbbVie(2 entities) | 25 | $547 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $491 |
| Lilly USA, LLC | 21 | $395 |
| Johnson & Johnson | 28 | $386 |
| AstraZeneca | 22 | $337 |
| Merck | 22 | $312 |
| Pfizer | 18 | $261 |
| Teva Pharmaceuticals USA, Inc. | 4 | $237 |
| Amgen | 14 | $209 |
| Otsuka America Pharmaceutical, Inc. | 9 | $156 |
| Neurocrine Biosciences, Inc. | 8 | $111 |
| Boehringer Ingelheim | 7 | $101 |
| Collegium Pharmaceutical, Inc. | 6 | $86 |
| Avanir Pharmaceuticals, Inc. | 6 | $85 |
| Sun Pharmaceutical Industries Inc. | 4 | $82 |
| Lundbeck LLC | 5 | $77 |
| Mylan Specialty L.p. | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Novartis | 5 | $63 |
| GSK | 4 | $62 |
| Abbott | 3 | $60 |
| Exact Sciences | 3 | $60 |
| Bayer | 3 | $53 |
| Alk-abello, Inc | 3 | $45 |
| Boston Scientific | 1 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Almatica Pharma LLC | 2 | $28 |
| Astellas Pharma US Inc | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Cequr Corporation | 2 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Corcept Therapeutics | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$250
- Austedo XR$223
- MOUNJARO$122
How this compares
$5,591 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 560 | $175,918 |
| JardianceEmpagliflozin | 117 | $63,283 |
| XifaxanRifaximin | 14 | $57,744 |
| MounjaroTirzepatide | 40 | $44,005 |
| FarxigaDapagliflozin Propanediol | 46 | $32,881 |
| XareltoRivaroxaban | 74 | $31,369 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $31,315 |
| OzempicSemaglutide | 26 | $30,291 |
| JanuviaSitagliptin Phosphate | 37 | $22,799 |
| RybelsusSemaglutide | 22 | $20,291 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $19,803 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $15,610 |
| TrulicityDulaglutide | 14 | $13,847 |
| EntrestoSacubitril/Valsartan | 26 | $13,796 |
| MyrbetriqMirabegron | 43 | $13,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $261 | $175,918560 claims |
| Boehringer IngelheimJardiance, Tradjenta | $101 | $72,044148 claims |
| MerckJanumet, Januvia, Janumet Xr | $312 | $67,08075 claims |
| Lilly USA, LLCMounjaro, Trulicity | $395 | $57,85354 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $491 | $57,74414 claims |
| Novo NordiskOzempic, Rybelsus | $939 | $50,58248 claims |
| AstraZenecaFarxiga, Lokelma | $337 | $48,49170 claims |
| Johnson & JohnsonXarelto | $386 | $31,36974 claims |
| GSKBreo Ellipta | $62 | $19,80342 claims |
| NovartisEntresto | $63 | $13,79626 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $13,33943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Englewood
- Nandita JoshiEnglewood$243K
- Srikant KondapaneniEnglewood$152K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.